ReviewJournal of global oncology2018
Facing the Global Challenges of Access to Cancer Medication.
Abstract readReview
In one paragraph
Review in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The high price of innovation: addressing financial toxicity and healthcare inequity in gynecological malignancies.Frontiers in oncology · 2026Article
- Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.Heliyon · 2024Review
- Volume-Outcome Relationship in Cancer Survival Rates: Analysis of a Regional Population-Based Cancer Registry in Japan.Healthcare (Basel, Switzerland) · 2022Article
- The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.The oncologist · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Abdul Raman JaziehAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Abdulaziz H Al-SaggabiAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Mark McClungAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Robert CarlsonAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Lowell E SchnipperAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Alexandru EniuAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Barri BlauveltAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Yousuf ZafarAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
David KerrAbdul Raman Jazieh and Abdulaziz H. Al-Saggabi, National Guard Health Affairs, Riyadh, Saudi Arabia; Mark McClung, Amgen Oncology, Thousand Oaks, CA; Robert Carlson, National Comprehensive Cancer Network, Fort Washington, PA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center; Barri Blauvelt, University of Massachusetts, Boston, MA; Alexandru Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania; Yousuf Zafar, Duke Cancer Institute, Durham, NC; and David Kerr, Oxford University, Oxford, United Kingdom.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Delivery of Health CareHealth Services AccessibilityDisease ManagementDrug IndustryGlobal HealthHealth PersonnelHumansNeoplasmsPublic Health Surveillance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.